As mentioned earlier, PIK3CA mutation and TP53 mutation are exclusive in GC, so for TP53 mutation negative patients, T cell immunotherapy based on PIK3CA H1047R may be an option, and it is also a potential choice for breast cancer or other cancer types that are resistant to targeted drugs. The gene discussed is TP53; the disease is cancer.